Company / Capital Expenditures
RELMADA THERAPEUTICS, INC. Capital Expenditures History
FY2013-FY2013 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-$1.8K
FY2013
5-year range
-$1.8K / -$1.8K
FY2013-FY2013
Trend
-
vs FY2012
Sector context
Sector data unavailable
Latest sector comparison
What the data says
-$1,800 in FY2013.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2013 | -$1.8K | - |
As of FY2013 · SEC 10-K · Updated Jun 28, 2026